66 related articles for article (PubMed ID: 8883617)
1. Antigenic determinants on HIV-1 envelope glycoproteins: a dickens of a time with oligomer twist.
Kent KA; Robinson J
AIDS; 1996; 10 Suppl A():S107-14. PubMed ID: 8883617
[No Abstract] [Full Text] [Related]
2. HIV vaccine design and the neutralizing antibody problem.
Burton DR; Desrosiers RC; Doms RW; Koff WC; Kwong PD; Moore JP; Nabel GJ; Sodroski J; Wilson IA; Wyatt RT
Nat Immunol; 2004 Mar; 5(3):233-6. PubMed ID: 14985706
[No Abstract] [Full Text] [Related]
3. Epitopes of HIV-1 glycoproteins recognized by the human immune system.
Laal S; Zolla-Pazner S
Chem Immunol; 1993; 56():91-111. PubMed ID: 7680869
[No Abstract] [Full Text] [Related]
4. Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 (HIV-1) isolates: effect on HIV-1 infection of macrophages and peripheral blood mononuclear cells.
Stamatatos L; Zolla-Pazner S; Gorny MK; Cheng-Mayer C
Virology; 1997 Mar; 229(2):360-9. PubMed ID: 9126249
[TBL] [Abstract][Full Text] [Related]
5. Structural biology: images from the surface of HIV.
Burton DR
Nature; 2006 Jun; 441(7095):817-8. PubMed ID: 16778874
[No Abstract] [Full Text] [Related]
6. [Evaluation of a recombinant latex agglutination test for HIV-1].
Pena MJ; Lafarga B; Pérez MC
Enferm Infecc Microbiol Clin; 1991; 9(6):380-1. PubMed ID: 1932250
[No Abstract] [Full Text] [Related]
7. Antibody neutralization and escape by HIV-1.
Wei X; Decker JM; Wang S; Hui H; Kappes JC; Wu X; Salazar-Gonzalez JF; Salazar MG; Kilby JM; Saag MS; Komarova NL; Nowak MA; Hahn BH; Kwong PD; Shaw GM
Nature; 2003 Mar; 422(6929):307-12. PubMed ID: 12646921
[TBL] [Abstract][Full Text] [Related]
8. Human immunodeficiency virus type 1 subtype E envelope recombinant peptides containing naturally immunogenic epitopes.
Chang SY; Vithayasai V; Vithayasai P; Essex M; Lee TH
J Infect Dis; 2000 Aug; 182(2):442-50. PubMed ID: 10915074
[TBL] [Abstract][Full Text] [Related]
9. Antigenic properties of recombinant envelope glycoproteins derived from T-cell-line-adapted isolates or primary human immunodeficiency virus isolates and their relationship to immunogenicity.
Brand D; Lemiale F; Thibault G; Verrier B; Lebigot S; Roingeard P; Buzelay L; Brunet S; Barin F
Virology; 2000 Jun; 271(2):350-62. PubMed ID: 10860888
[TBL] [Abstract][Full Text] [Related]
10. The antigenic structure of the HIV gp120 envelope glycoprotein.
Wyatt R; Kwong PD; Desjardins E; Sweet RW; Robinson J; Hendrickson WA; Sodroski JG
Nature; 1998 Jun; 393(6686):705-11. PubMed ID: 9641684
[TBL] [Abstract][Full Text] [Related]
11. An early taste of functional glycomics.
Mrksich M
Chem Biol; 2004 Jun; 11(6):739-40. PubMed ID: 15217604
[No Abstract] [Full Text] [Related]
12. Effects of oligomerization on the epitopes of the human immunodeficiency virus type 1 envelope glycoproteins.
Gorny MK; VanCott TC; Williams C; Revesz K; Zolla-Pazner S
Virology; 2000 Feb; 267(2):220-8. PubMed ID: 10662617
[TBL] [Abstract][Full Text] [Related]
13. Neutralization sensitivity of a simian-human immunodeficiency virus (SHIV-HXBc2P 3.2N) isolated from an infected rhesus macaque with neurological disease.
Song B; Cayabyab M; Phan N; Wang L; Axthelm MK; Letvin NL; Sodroski JG
Virology; 2004 Apr; 322(1):168-81. PubMed ID: 15063126
[TBL] [Abstract][Full Text] [Related]
14. Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission.
Derdeyn CA; Decker JM; Bibollet-Ruche F; Mokili JL; Muldoon M; Denham SA; Heil ML; Kasolo F; Musonda R; Hahn BH; Shaw GM; Korber BT; Allen S; Hunter E
Science; 2004 Mar; 303(5666):2019-22. PubMed ID: 15044802
[TBL] [Abstract][Full Text] [Related]
15. Immunology. Close to the edge: neutralizing the HIV-1 envelope.
Nabel GJ
Science; 2005 Jun; 308(5730):1878-9. PubMed ID: 15976295
[No Abstract] [Full Text] [Related]
16. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites.
Kwong PD; Doyle ML; Casper DJ; Cicala C; Leavitt SA; Majeed S; Steenbeke TD; Venturi M; Chaiken I; Fung M; Katinger H; Parren PW; Robinson J; Van Ryk D; Wang L; Burton DR; Freire E; Wyatt R; Sodroski J; Hendrickson WA; Arthos J
Nature; 2002 Dec; 420(6916):678-82. PubMed ID: 12478295
[TBL] [Abstract][Full Text] [Related]
17. AIDS/HIV. Developing an AIDS vaccine: need, uncertainty, hope.
Emini EA; Koff WC
Science; 2004 Jun; 304(5679):1913-4. PubMed ID: 15218131
[No Abstract] [Full Text] [Related]
18. Antibodies to conserved epitopes of the HIV-1 envelope in sera from long-term non-progressors: prevalence and association with neutralizing activity.
Braibant M; Brunet S; Costagliola D; Rouzioux C; Agut H; Katinger H; Autran B; Barin F
AIDS; 2006 Oct; 20(15):1923-30. PubMed ID: 16988513
[TBL] [Abstract][Full Text] [Related]
19. HIV vaccines. Magic of the occult?
Montefiori D; Moore JP
Science; 1999 Jan; 283(5400):336-7. PubMed ID: 9925493
[No Abstract] [Full Text] [Related]
20. HIV-1 neutralization: mechanisms and relevance to vaccine design.
Zwick MB; Burton DR
Curr HIV Res; 2007 Nov; 5(6):608-24. PubMed ID: 18045117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
